Gresham House Ventures

Gresham House Ventures sits in the slice of the UK market that gets overlooked by both London seed funds and US growth shops. The firm is the venture arm of Gresham House plc, a specialist asset manager, and it deploys growth equity into established UK technology and tech-enabled healthcare businesses that have already pushed past early product risk and need fuel to scale. Founders working on physician-facing AI and clinical software tools tend to find the firm useful once initial reference customers are signed and the question is operational repeatability rather than science.

The thesis is intentionally narrow. Gresham House Ventures looks for software and services companies with proven commercial traction, a defensible market position, and a credible path to profitability. Within healthcare, the team gravitates toward Health IT, healthcare software, and broader digital health platforms that sell into the NHS, private providers, payers, and large employers. AI is a feature, not a category for them, which means a clinical AI startup is evaluated on revenue quality and contract economics rather than model novelty.

Check sizes typically land between one and five million dollars at Series A, Series B, and growth rounds, often as part of a larger syndicate. The firm invests almost exclusively in UK-headquartered companies and tends to stay involved through follow-on rounds, including bridge and structured equity, when execution is on track. Founders raising a first institutional round before commercial proof points are usually too early. Founders with two to ten million in recurring revenue, healthy gross margins, and a clear ICP are squarely in scope.

Gresham House Ventures operates as a structured, partner-led team housed inside the wider Gresham House platform, which gives portfolio companies access to public-market capital relationships and broader corporate finance expertise. The investment professionals tend to come from growth equity, private equity, and operating backgrounds rather than pure technical roles, so diligence is heavy on financials, customer cohorts, and unit economics.

The right way to approach the firm is through a warm introduction from an existing portfolio CEO, a UK growth-stage advisor, or a corporate finance contact already working with Gresham House. Cold inbound through the website is read but converts less often. When you reach out, lead with the metrics: ARR, net revenue retention, sales cycle length, payback period, NHS or private contract pipeline, and a defensible view on regulatory positioning. A clean data room signals seriousness and shortens the diligence path. The firm prefers to meet companies a quarter or two before a round opens, which gives the team time to do reference calls and form a view on the market without time pressure. If you are a UK clinical AI or health IT founder with real customers, real revenue, and a credible plan to compound, Gresham House Ventures is a sensible name to have on your list. If you are pre-revenue or chasing a frontier-research story, you will get further with a seed-stage specialist and can revisit later.